Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study

Venkatraman N., Silman D., Bellamy D., Stockdale L., Bowyer G., Edwards NJ., Griffiths O., Lopez FR., Powlson J., Mair C., Folegatti PM., Datoo MS., Morter R., Minassian AM., Poulton I., Collins KA., Brod F., Angell-Manning P., Berrie E., Brendish N., Glenn G., Fries L., Baum J., Blagborough AM., Roberts R., Lawrie AM., Angus B., Lewis DJM., Faust SN., Ewer KJ., Hill AVS.